These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19940840)

  • 21. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population.
    Fabrizi F; Cerutti R; Nardelli L; Tripodi F; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):49-56. PubMed ID: 31327620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients.
    Vilajeliu A; Sequera VG; García-Basteiro AL; Sicuri E; Aldea M; Velasco C; Bayas JM
    Hum Vaccin Immunother; 2016 Sep; 12(9):2317-21. PubMed ID: 27105182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders.
    Jha R; Lakhtakia S; Jaleel MA; Narayan G; Hemlatha K
    Ren Fail; 2001 Sep; 23(5):629-36. PubMed ID: 11725909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed.
    Prescrire Int; 2008 Dec; 17(98):234-6. PubMed ID: 19422145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection.
    Chaves SS; Daniels D; Cooper BW; Malo-Schlegel S; Macarthur S; Robbins KC; Kobetitsch JF; McDaniel A; D'Avella JF; Alter MJ
    Vaccine; 2011 Dec; 29(52):9618-23. PubMed ID: 22044739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 33423842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
    Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
    Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.
    Tung J; Carlisle E; Smieja M; Kim PT; Lee CH
    Am J Kidney Dis; 2010 Oct; 56(4):713-9. PubMed ID: 20630640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years.
    Kurugöl Z; Mutlubaş F; Ozacar T
    Vaccine; 2005 Apr; 23(22):2876-80. PubMed ID: 15780736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients.
    Beran J
    Expert Opin Biol Ther; 2008 Feb; 8(2):235-47. PubMed ID: 18194079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
    Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
    Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 36165374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
    Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
    Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
    Janssen JM; Heyward WL; Martin JT; Janssen RS
    Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines.
    Grzegorzewska AE
    Expert Rev Vaccines; 2014 Nov; 13(11):1317-26. PubMed ID: 25148051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.